in vivo– tag –
-
In Vivo CAR T-cell Generation Advances: VivoVec Platform Streamlines Manufacturing and Treatment Workflows, Reducing Lymphodepletion Dependence
Frontiers International Overview Advances in in vivo CAR T-cell generation, particularly platforms like VivoVec, show potential to simplify manufacturing and treatment workflows by enhancing CAR T-cell expansion and persistence. This app... -
iPSC Therapies: Manufacturing Consistency Requires Preserving Cell Functionality Beyond Basic Properties, Integrating Cell Line Selection and Genetic Engineering
Pharma's Almanac USA Overview An article in Pharma's Almanac highlights that iPSC-derived cardiomyocyte products, even with similar identity and purity, can exhibit differing functional performance, emphasizing the critical need to chara... -
Antibody-Drug Conjugates Prepared with Peptide Asparaginyl Ligase Enhance Uniformity and Antitumor Activity, Promising Pharmaceutical Applications
Molecular Cancer Therapeutics (AACR Journals) USA Overview Novel antibody-drug conjugates (ADCs) prepared using peptide asparaginyl ligase (PAL) demonstrated potent antitumor activity in both in vitro and in vivo models. This innovative ... -
Novel TROP2-Targeting ADC, hIMB1636-LDP-AE, Demonstrates Potent Antitumor Efficacy and Anti-Cancer Stem Cell Activity in Breast and Lung Cancers
Medium (@wuhanmabnus) China Overview A novel antibody-drug conjugate (ADC), hIMB1636-LDP-AE, engineered through genetic and molecular recombination technologies, has demonstrated potent antitumor efficacy in both in vitro and in vivo mod... -
Huazhong University of Science and Technology Tongji Hospital Demonstrates In Vivo CAR-T Therapy, Achieving Cost Reduction and Immune Reset for Multiple Sclerosis
Chosunbiz South Korea Overview A research team at Huazhong University of Science and Technology Tongji Hospital has demonstrated in vivo CAR-T therapy for autoimmune diseases like multiple sclerosis, successfully reducing manufacturing a... -
GentiBio Publishes in EMBO Molecular Medicine, Detailing Technology Enabling Durable Persistence of Allogeneic T-Cell Therapies
GentiBio (Press Release) USA Overview GentiBio announced the publication in EMBO Molecular Medicine of a paper detailing an innovative technology enabling durable in vivo persistence of allogeneic T-cell therapies. This approach addresse... -
Celvivo Secures $6.6M to Propel Advanced 3D Cell Culture Platform, Appoints New CEO for Commercial Scale-Up
Dealroom News Denmark Overview Danish biotech Celvivo has raised $6.6 million from a mix of existing and new investors, earmarked for the accelerated commercial expansion of its ClinoStar 3D cell culture platform. This platform, which ge... -
Lonza and Entropic Unveil Scalable 96-Well 3D Human Skin Organoid Platform for Accelerated Screening
Scientist.com Switzerland Overview Lonza and Entropic have jointly developed a scalable 96-well 3D human skin organoid model, dramatically improving the efficiency of skin barrier function and injury screening. Utilizing Entropic's ZYRAL... -
ABM Unveils Spheroid & Organoid Medium Portfolio to Revolutionize 3D Culture Workflows for Drug Discovery and Disease Modeling
ABM (via Facebook) International Overview ABM has launched a new Spheroid & Organoid Medium portfolio designed to robustly support reproducible and scalable 3D culture workflows for drug discovery and disease modeling. This new produ... -
TScan Therapeutics Pivots to In Vivo TCR-T Therapy, Halting Allogeneic Cell Program TSC-101 Amidst Manufacturing Challenges
FirstWord Pharma USA Overview TScan Therapeutics announced a strategic pivot, discontinuing its lead allogeneic cell therapy program, TSC-101, and shifting focus to preclinical in vivo TCR-T candidates for solid tumors, citing funding co...
